Edition:
United States

Synlogic Inc (SYBX.OQ)

SYBX.OQ on NASDAQ Stock Exchange Global Market

10.23USD
14 Dec 2017
Change (% chg)

$-0.03 (-0.29%)
Prev Close
$10.26
Open
$10.21
Day's High
$11.00
Day's Low
$10.21
Volume
20,077
Avg. Vol
5,291
52-wk High
$23.00
52-wk Low
$8.83

Latest Key Developments (Source: Significant Developments)

Synlogic, Ginkgo Bioworks To Collaborate To Discover New Living Medicines To Treat Neurological And Liver Disorders
Friday, 8 Dec 2017 06:00am EST 

Dec 8 (Reuters) - Synlogic Inc ::SYNLOGIC INC - CO, ORGANISM COMPANY GINKGO BIOWORKS TO COLLABORATE TO DISCOVER NEW LIVING MEDICINES TO TREAT NEUROLOGICAL AND LIVER DISORDERS.  Full Article

Synlogic qtrly loss per share $1.66‍​
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Synlogic Inc ::Synlogic reports third quarter 2017 financial results and recent progress.Q3 revenue $100,000.Synlogic Inc - qtrly loss per share $1.66‍​.  Full Article

Synlogic says ‍SYNB1020 was safe, well tolerated in subjects
Wednesday, 8 Nov 2017 08:00am EST 

Nov 8 (Reuters) - Synlogic Inc :Synlogic reports positive top-line phase 1 data demonstrating safety and tolerability and proof of mechanism in healthy volunteers for synb1020, a synthetic biotictm medicine for the treatment of hyperammonemia.Synlogic inc - ‍data support initiation of two phase 1b/2a studies in 2018​.Synlogic - ‍synb1020 was safe, well tolerated in subjects in multiple ascending dose cohorts.Synlogic - ‍there have been no serious adverse events, no cases of infection with bacteria in synb1020 study ​.  Full Article

Synlogic says co entered into sales agreement with Cowen And Company, LLC ​
Monday, 16 Oct 2017 04:22pm EDT 

Oct 17 (Reuters) - Synlogic Inc :Synlogic Inc - ‍on October 13, 2017 co entered into a sales agreement with Cowen And Company, LLC - SEC filing ​.Synlogic Inc - pursuant to agreement co may offer and sell, shares of its common stock, par value $0.001 per share having an offering price of up to $50 million.  Full Article

‍OrbiMed Advisors reports 8.08 pct stake in Synlogic Inc - SEC filing
Thursday, 7 Sep 2017 02:27pm EDT 

Sept 7 (Reuters) - OrbiMed Advisors LLC::‍OrbiMed Advisors LLC​ reports 8.08 percent stake in Synlogic Inc as of Aug 28 - SEC filing.  Full Article

Deerfield Management Co LP reports 5.22 pct passive stake in Synlogic as on Aug 28 - SEC Filing‍​
Wednesday, 6 Sep 2017 06:25am EDT 

Sept 6 (Reuters) - Synlogic Inc :Deerfield Management Company, L.P. reports 5.22 percent passive stake in Synlogic Inc as on August 28, 2017 - SEC Filing‍​.  Full Article

Synlogic and Mirna therapeutics agree to merger
Tuesday, 16 May 2017 06:30am EDT 

May 16 (Reuters) - Mirna Therapeutics Inc :Synlogic and Mirna Therapeutics agree to merger.Mirna Therapeutics Inc says first clinical trial for lead Synlogic product candidate anticipated to start mid-2017.Says Synlogic closes $42 million of series C preferred stock financing by leading biotechnology investors.Mirna Therapeutics Inc - combined company well-capitalized with approximately $82 million in cash expected at closing from merger and series C.Mirna Therapeutics Inc - following merger, current Synlogic shareholders are expected to own approximately 83 percent of combined company.Says by mid-2017, Synlogic plans to initiate a phase 1 healthy volunteers study for its lead candidate, SYNB1020.Mirna Therapeutics Inc - transaction has been approved by board of directors of both companies.Mirna Therapeutics Inc - Synlogic will merge with a wholly owned subsidiary of Mirna in an all-stock transaction.Mirna Therapeutics Inc - following merger, Jose Carlos Gutierrez-Ramos, Synlogic's chief executive officer will become chief executive officer of merged company.Says following merger, current Mirna stockholders will own approximately 17 percent of combined company.Mirna Therapeutics Inc - merged company will continue under Synlogic name.Mirna Therapeutics Inc - following merger, board will be comprised of seven directors, including two directors currently serving on Mirna's board.  Full Article

Mirna Therapeutics qtrly loss per share $0.24
Tuesday, 9 May 2017 06:21pm EDT 

May 9 (Reuters) - Mirna Therapeutics Inc :Mirna Therapeutics Inc qtrly loss per share $0.24.  Full Article

Mirna therapeutics reports Q1 2017 financial results
Tuesday, 9 May 2017 05:30pm EDT 

May 9 (Reuters) - Mirna Therapeutics Inc ::Mirna Therapeutics reports first quarter 2017 financial results.Says net loss was approximately $5.0 million for three months ended March 31, 2017.  Full Article

Mirna Therapeutics qtrly net loss attributable to common stockholders $8.7 mln vs $8.9 mln
Tuesday, 14 Mar 2017 06:11pm EDT 

Mirna Therapeutics Inc : Mirna therapeutics reports financial results for the fourth quarter and full year ended december 31, 2016 . Mirna therapeutics inc - engaged a financial advisor and has been pursuing activities to identify and evaluate strategic alternatives . Mirna therapeutics inc - pursuing activities to identify and evaluate strategic alternatives, including a possible merger or sale of company . Mirna therapeutics inc - qtrly net loss attributable to common stockholders $8.7 million versus $8.9 million . Mirna therapeutics - strategic process is active and ongoing and co is pursuing discussions with third parties on a range of potential transactions .Mirna therapeutics- expects to incur additional restructuring charges under u.s. Gaap of about $0.3 million through six months ended june 30, 2017.  Full Article